Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.
about
The 2014–2015 Ebola outbreak in West Africa: Hands OnUse of Unamplified RNA/cDNA-Hybrid Nanopore Sequencing for Rapid Detection and Characterization of RNA VirusesA Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary ReportMonitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in LiberiaEbola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra LeoneEbolavirus Evolution: Past and PresentAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksUnderstanding Ebola: the 2014 epidemicEvolution and Spread of Ebola Virus in Liberia, 2014-2015Error baseline rates of five sample preparation methods used to characterize RNA virus populationsThe Disinfection Characteristics of Ebola Virus Outbreak Variants[Overview of the Ebola vaccines in pre-clinical and clinical development].Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.In silico analysis suggests interaction between Ebola virus and the extracellular matrixEvaluation of Signature Erosion in Ebola Virus Due to Genomic Drift and Its Impact on the Performance of Diagnostic Assays.Molecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra LeoneState-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola VirusMechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.Ebola Virus Infection: Overview and Update on Prevention and Treatment.Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency.Clinical Evaluation of Ebola Virus Disease Therapeutics.Genomic Analysis of Viral Outbreaks.Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences.EbolaID: An Online Database of Informative Genomic Regions for Ebola Identification and Treatment.Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center.Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone.Unveiling a Drift Resistant Cryptotope within Marburgvirus Nucleoprotein Recognized by Llama Single-Domain Antibodies.United States FDA's emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future.Sequence Optimized Real-Time Reverse Transcription Polymerase Chain Reaction Assay for Detection of Crimean-Congo Hemorrhagic Fever Virus.Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.Generation of therapeutic antisera for emerging viral infections
P2860
Q24049114-B3449639-A88A-41D5-B139-80C9520F4689Q24261122-D3D12C02-EF89-47BD-9A27-FBCB39D6576CQ24289295-D40FC249-9433-4400-A34C-9B4C8CC8B45EQ24696012-2E49FF14-C7CA-484B-B665-BFA85DF0C7C0Q24696014-BEC6A705-815F-46C9-B664-04C130A22FBDQ26777336-6D8FF491-AD6E-471F-91B8-4C30D8336E13Q26801423-868975FE-B5C4-4AF8-898E-850C03D10F34Q26970771-49A2DD8C-E212-4D87-9B1D-C009E7378BABQ28383959-70D5E9F8-04C7-4178-9D41-996BB901987DQ29048645-6452D9AE-3A2A-4553-9567-9200C710CBDBQ29048646-653FF263-B0EA-4E39-95BD-0BA141FDE766Q30245207-4331513A-5026-4DC7-8A7D-EF1AEBDD087FQ34473079-C6FD48E5-0F59-4F62-B6AC-DC51FB337C34Q35099536-A3776ED8-436D-4A91-9A01-13A09ECC227EQ35668373-8DA1FA4B-40F5-454E-B29F-B49182FE4189Q35756962-35CCC0C7-C3C0-493E-B386-C65286C4ED4AQ36043209-CD3EF1FF-C7F4-4897-9ACE-C9164A82CECBQ36208191-6F8936C8-4740-42D0-9678-F7EC37D77F35Q36239796-FE006A89-F7D0-4D52-8143-E5BCE63AA52CQ36363253-9212E8E7-000D-4429-B411-3F120D91904AQ36654562-60A5F83E-1FE2-4221-ABAF-DC3A29E33920Q36736898-0FC8FD39-81A2-4757-BABC-991B9097857CQ38617605-76C588C2-02BD-4A48-9A7A-3FDFF417AEC1Q38833446-6CBA7A63-5185-4A91-9A88-6971D998DD69Q40092794-E2895731-C6EB-4136-9309-918DF5A19935Q40095779-765E24C0-7D6D-499A-8E3F-62A3F2D9021FQ40114945-C701688B-44D7-40ED-800F-ADF960EDDC8BQ40156229-5D46E0D2-BA1F-46F7-B40E-333044242BB8Q42371906-CB3E0C54-F060-4AD6-B2DB-568664FA4210Q44100339-234E0F94-8DE1-437B-8227-0E2A1D0789E5Q45324424-AD68AF58-CF4E-475B-BFAC-FED2F7E9AF7EQ53687216-C515B495-4825-4009-94DF-3A1FAFEBF1DEQ57483199-F5276488-5AD0-4FFD-BB74-E618281AE357
P2860
Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Evaluation of the potential im ...... -based candidate therapeutics.
@ast
Evaluation of the potential im ...... -based candidate therapeutics.
@en
type
label
Evaluation of the potential im ...... -based candidate therapeutics.
@ast
Evaluation of the potential im ...... -based candidate therapeutics.
@en
altLabel
Evaluation of the potential im ...... e-based candidate therapeutics
@en
prefLabel
Evaluation of the potential im ...... -based candidate therapeutics.
@ast
Evaluation of the potential im ...... -based candidate therapeutics.
@en
P2093
P2860
P50
P356
P1433
P1476
Evaluation of the potential im ...... -based candidate therapeutics.
@en
P2093
Aaron E Lin
Daniel J Park
Jeffrey R Kugelman
Rachel Sealfon
Stephen Gire
P2860
P356
10.1128/MBIO.02227-14
P407
P50
P577
2015-01-20T00:00:00Z